Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
IND submitted for systemic sclerosis and 50% recruitment milestone in Phase II study reached Stockholm, Sweden, June 14 2021 – Gesynta Pharma AB today announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across Europe have been recruited. The study investigates the safety of GS-248 and its efficacy on Raynaud’s phenomenon and peripheral vascular blood flow. Top-